La Trobe

Prevalence and correlates of simultaneous, multiple substance injection (co-injection) among people who inject drugs in Melbourne, Australia

Download (544.63 kB)
journal contribution
posted on 2025-11-27, 03:13 authored by Anna Palmer, Peter HiggsPeter Higgs, N Scott, P Agius, L Maher, Paul Dietze
<p dir="ltr">Aims: To estimate the prevalence of and risk factors associated with concurrent injection of multiple substances (co-injection) among a community-recruited cohort of people who inject drugs. </p><p dir="ltr">Design: Cross-sectional study. </p><p dir="ltr">Setting: Melbourne, Australia. </p><p dir="ltr">Participants: A sample of 720 actively injecting participants from the Melbourne Injecting Drug User Cohort Study (33% female) was extracted. </p><p dir="ltr">Measurements: We constructed two statistical models: a logistic regression model analysing correlates of co-injection of any substance combination in the past month and a multinomial logistic regression model analysing correlates of three mutually exclusive groups: heroin–diphenhydramine co-injection only, co-injection of other substances and no co-injection. Risk factors examined included drug use characteristics, demographic characteristics, health service use, hepatitis C status, injection risk behaviours and previous experience of non-fatal overdose. </p><p dir="ltr">Findings: One-third [n = 226, 31%; 95% confidence interval (CI): 28–34%] of participants reported co-injecting substances within the past month, with equal numbers of participants reporting injecting combinations of heroin–diphenhydramine (n = 121, 54%; 95% CI = 48–60%) and heroin–methamphetamine (n = 121, 54%; 95% CI = 48–60%). In logistic regression analyses, reporting co-injection of any substance combination was associated with male sex [adjusted odds ratio (aOR) = 1.80, 95% CI = 1.18–2.74, P = 0.006] and injecting daily or more frequently (aOR = 2.04, 95% CI = 1.31–3.18, P = 0.002). In multinomial logistic regression analyses, participants reporting heroin–diphenhydramine co-injection only were significantly more likely to report groin injecting [adjusted relative risk ratio (aRRR) = 6.16, 95% CI = 2.80–13.56, P < 0.001] and overdose (requiring an ambulance) in the past 12 months (aRRR = 2.81, 95% CI = 1.17–6.72, P = 0.021) compared with participants reporting no co-injection or co-injection of other substances. </p><p dir="ltr">Conclusions: A substantial proportion of people who inject drugs report co-injection of multiple substances, which is associated with a range of socio-demographic, drug use and health service use risk factors.</p>

Funding

P.H. has received funding from Gilead Science and Abbvie for investigator-initiated research unrelated to this study. P.D. has received an investigator-driven grant from Gilead Sciences for unrelated work on hepatitis C and an untied educational grant from Reckitt Benckiser for unrelated work on the introduction of buprenorphine-naloxone into Australia.

History

Publication Date

2021-04-01

Journal

Addiction

Volume

116

Issue

4

Pagination

13p. (p. 876-888)

Publisher

Wiley

ISSN

0965-2140

Rights Statement

© 2020 Society for the Study of Addiction This is the peer reviewed version of the following article: Palmer A, et al (2021). Prevalence and correlates of simultaneous, multiple substance injection (co-injection) among people who inject drugs in Melbourne, Australia. Addiction, 116(4), 876-888, which has been published in final form at http://doi.org/10.1111/add.15217. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

Usage metrics

    Journal Articles

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC